Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239D

NCT05660265 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05660265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05660265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239D
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
August 26, 2023
Completion date
September 22, 2025
Enrollment
11 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

anaemia, sickle cell, hematologic diseases